AOB Pharma has advanced its Phase 2b clinical trial of ammonia-oxidizing bacteria (AOB) for acne treatment, with results showing a statistically significant 2-point reduction in acne severity compared to vehicle control at the 12-week mark. The trial, executed in partnership with clinical research organization Biorasi, targeted patients with moderate to severe acne vulgaris and represents the first-of-its-kind investigation into live topical bacterial treatment for acne.
This milestone marks a significant step forward for a therapeutic approach that fundamentally differs from conventional acne treatments like retinoids, antibiotics, and benzoyl peroxide. The Phase 2b findings demonstrate that topical application of Nitrosomonas eutropha—a single strain of beneficial bacteria—can produce measurable clinical improvement in acne severity. With an FDA protocol submission planned for July 10, the program is progressing toward potential Phase 3 evaluation, which would bring the treatment closer to regulatory review for broader patient access.
Table of Contents
- What Is AOB Pharma’s Phase 2b Trial and Its Timeline?
- How Does Ammonia-Oxidizing Bacteria Work Against Acne?
- Phase 2b Results: Understanding the IGA Efficacy Endpoint
- Live Bacterial Treatment: How This Approach Differs from Conventional Acne Therapies
- Limitations and Important Considerations About the Trial
- Manufacturing, Stability, and Practical Delivery Challenges
- What Moderate to Severe Acne Patients Should Know Now
What Is AOB Pharma’s Phase 2b Trial and Its Timeline?
AOB Pharma partnered with Biorasi, a contract research organization specializing in clinical trial execution, to conduct the Phase 2b study in moderate to severe acne vulgaris. This partnership represents a critical phase in the development pathway, as Phase 2b trials are designed to further evaluate efficacy and safety in a larger patient population than earlier Phase 2a studies, while also testing optimal dosing strategies. The program’s progression to an FDA protocol submission scheduled for july 10 indicates the company’s commitment to advancing toward Phase 3 requirements, which typically involve even larger patient cohorts and longer duration of treatment observation.
Phase 2b trials bridge the gap between early proof-of-concept work and the definitive efficacy trials required for regulatory approval. For acne treatments specifically, this phase must demonstrate not only statistical improvement in standardized severity measures but also acceptable safety profiles in the target patient population. The selection of moderate to severe acne as the initial focus population is strategic—these patients typically have fewer effective options compared to those with mild acne, and they represent a population with significant unmet medical need.
How Does Ammonia-Oxidizing Bacteria Work Against Acne?
Nitrosomonas eutropha, the active ingredient in AOB Pharma’s formulation, is a nitrifying bacterium that metabolizes ammonia on the skin surface. The proposed mechanism of action centers on the skin’s microbiome—the complex community of microorganisms that live on human skin. Acne pathogenesis involves multiple factors including Cutibacterium acnes (formerly Propionibacterium acnes) overgrowth, sebum production, follicular hyperkeratinization, and inflammation.
By introducing a beneficial bacterial strain that competes for nutrients and alters the skin’s chemical environment, the treatment theoretically restores microbial balance and reduces conditions favorable for acne-causing bacteria. This live bacterial approach represents a departure from traditional acne therapeutics, which typically work through antimicrobial action (killing bacteria), anti-inflammatory pathways, or sebum reduction. A critical limitation of conventional treatments is that prolonged use of oral or topical antibiotics can select for resistant bacterial strains and disrupt the skin microbiome, potentially leading to treatment resistance or skin irritation. The ammonia-oxidizing bacteria approach attempts to work with the skin’s natural ecology rather than against it, though long-term effects on skin microbiome composition and the durability of bacterial colonization remain open questions requiring further investigation.
Phase 2b Results: Understanding the IGA Efficacy Endpoint
The primary endpoint of the Phase 2b trial was a 2-point reduction in Investigator’s Global Assessment (IGA) of acne severity compared to vehicle control at week 12, achieved with statistical significance (p=0.03). The IGA is a standardized five-point scale used across acne clinical trials—ranging from 0 (clear) to 4 (severe)—that allows dermatologists to assign an objective grade to overall acne severity. A 2-point reduction represents meaningful clinical improvement; for example, a patient assessed at baseline as having moderate acne (IGA score of 3) would ideally reach an IGA score of 1 (almost clear) or lower by week 12.
The statistical significance level of p=0.03 means there is only a 3 percent probability that this observed difference occurred by chance alone, meeting the conventional threshold for efficacy claims. However, it is important to contextualize that while statistically significant, a 2-point IGA reduction, though clinically relevant, is not uniformly transformative across all patients. Individual patient responses in acne trials typically show substantial variability—some patients achieve dramatic clearance while others show modest improvement. The trial’s reporting of a mean reduction across the treatment group obscures this variability, which will become clearer when detailed Phase 2b data are published in peer-reviewed literature or presented at dermatology conferences.
Live Bacterial Treatment: How This Approach Differs from Conventional Acne Therapies
Traditional acne treatments fall into several categories: topical retinoids (tretinoin, adapalene, tazarotene) that promote skin cell turnover; topical or oral antibiotics (clindamycin, doxycycline) that suppress acne-causing bacteria; benzoyl peroxide, which both kills bacteria and promotes exfoliation; hormonal agents like oral contraceptives or spironolactone; and isotretinoin (Accutane), a powerful oral retinoid for severe cases. Each of these carries distinct tradeoffs regarding efficacy, side effects, and long-term viability. The ammonia-oxidizing bacteria approach offers a mechanistically novel alternative, though it trades some proven efficacy for the potential advantage of microbiome restoration.
Patients using systemic antibiotics for acne often experience gastrointestinal disruption and may develop resistant acne-causing bacteria over months to years of treatment. Retinoids frequently cause skin irritation, dryness, and photosensitivity, requiring gradual dose escalation and strict sun protection. A live bacterial treatment theoretically avoids these pitfalls by working with rather than against skin physiology. However, this is contingent on the bacteria establishing stable colonization and maintaining efficacy—questions that can only be answered through longer-term follow-up data and Phase 3 trials.
Limitations and Important Considerations About the Trial
The Phase 2b trial results, while encouraging, represent a single timepoint (week 12) assessment with a specific patient population. The 2-point IGA reduction is notably modest compared to some conventional treatments—for instance, topical retinoids often achieve 3- or 4-point reductions in IGA over 12 weeks in published trials, though direct comparison is complicated by differences in trial design and population characteristics. Additionally, the trial evaluated only one bacterial strain (Nitrosomonas eutropha) in a topical formulation; questions remain about whether other bacterial strains might be more effective, how the formulation maintains bacterial viability, and whether intermittent versus daily application offers the best risk-benefit profile.
A fundamental limitation of live biotherapeutic products is regulatory uncertainty. The FDA has limited experience approving live bacterial treatments for dermatologic indications, meaning the pathway forward involves some procedural ambiguity regarding manufacturing standards, stability testing, and long-term safety monitoring. Furthermore, because the treatment involves introducing live organisms to the skin, there is inherent risk of adverse effects in immunocompromised patients or those with disrupted skin barriers (severe dermatitis, open wounds, or burns). The Phase 2b trial likely enrolled relatively healthy subjects with acne as their primary condition, so real-world safety in more complex patient populations remains unexplored.
Manufacturing, Stability, and Practical Delivery Challenges
Live bacterial therapeutics present distinct manufacturing and stability challenges compared to conventional small-molecule drugs or even biologic proteins. The bacterial cells must remain viable during formulation, storage, and application, requiring careful attention to pH, osmolarity, preservative selection, and temperature control. Unlike topical creams or gels that remain chemically stable on pharmacy shelves for years, a living bacteria product may have a finite shelf life and specific storage requirements (refrigeration, protection from light, or other environmental constraints).
These practical considerations directly impact patient convenience, cost, and whether the treatment can be distributed through standard pharmacy channels without specialized handling. The formulation strategy employed by AOB Pharma—whether the product is delivered as a liquid suspension, a cream base, or another vehicle—will significantly influence both efficacy and patient adherence. Early-phase trials often use optimized research formulations that may differ substantially from the final commercial product, meaning the Phase 2b results reflect efficacy under specific formulation conditions that could shift during development.
What Moderate to Severe Acne Patients Should Know Now
Patients currently suffering from moderate to severe acne should recognize that AOB Pharma’s Phase 2b results, while scientifically noteworthy, do not yet translate to an available treatment option. The planned July 10 FDA protocol submission indicates the company is seeking guidance on Phase 3 trial design—the definitive efficacy and safety study required before regulatory approval can be considered.
Phase 3 typically requires 12 to 24 months of enrollment, data collection, and analysis, meaning that even with successful Phase 3 results, a minimum of two to four years likely remains before potential approval and market availability. For individuals with moderate to severe acne who have failed or experienced intolerance to conventional treatments, existing options remain retinoids (including isotretinoin for the most severe cases), oral antibiotics combined with topical agents, hormonal therapy, and in some cases light-based therapies. The ammonia-oxidizing bacteria treatment represents a promising investigational approach rather than a near-term solution, making it important for patients to continue working with dermatologists on proven therapeutic strategies while monitoring developments in the AOB Pharma program through clinical trial registration databases or the company’s official communications.
- —
